Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.60 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.60 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.60 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.60 |
| ▸ | P2RY2 | P41231 | 10/20 | 0.53 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.49 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23710653 | 1.00 | SLC28A1 (0.60) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL800228 | 1.00 | SLC28A1 (0.60) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL800550 | 1.00 | SLC28A1 (0.60) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL21275617 | 1.00 | SLC28A1 (0.60) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL16629728 | 1.00 | SLC28A1 (0.60) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL13174543 | 0.90 | SLC28A1 (0.54) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL13190779 | 0.90 | SLC28A1 (0.51) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL13190777 | 0.90 | SLC28A1 (0.51) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL5846581 | 0.89 | SLC28A1 (0.63) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL800388 | 0.88 | SLC28A1 (0.50) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4599889-A2 | SIRNA AND THEIR USE IN METHODS AND COMPOSITIONS FOR INHIBITING THE EXPRESSION OF THE NRARP GENE | Sylentis S.A.U. (ES) | 2025-08-13 | — | — | EP | claimed |
| EP-3347470-B1 | SIRNA AND THEIR USE IN METHODS AND COMPOSITIONS FOR INHIBITING THE EXPRESSION OF THE NRARP GENE | SYLENTIS SAU (ES) | 2025-07-09 | — | — | EP | claimed |
| WO-2025109162-A1 | SIRNA AND COMPOSITIONS FOR PROPHYLACTIC AND THERAPEUTIC TREATMENT OF OCULAR RETINAL CONDITIONS | SYLENTIS S.A.U. (ES) | 2025-05-30 | — | — | WO | claimed |
| WO-2025109166-A1 | SIRNA AND COMPOSITIONS FOR PROPHYLACTIC AND THERAPEUTIC TREATMENT OF OCULAR RETINAL CONDITIONS | SYLENTIS S.A.U. (ES) | 2025-05-30 | — | — | WO | claimed |
| EP-4560020-A1 | SIRNA AND COMPOSITIONS FOR PROPHYLACTIC AND THERAPEUTIC TREATMENT OF OCULAR RETINAL CONDITIONS | Sylentis S.A.U. (ES) | 2025-05-28 | — | — | EP | claimed |
| EP-4560019-A1 | SIRNA AND COMPOSITIONS FOR PROPHYLACTIC AND THERAPEUTIC TREATMENT OF OCULAR RETINAL CONDITIONS | Sylentis S.A.U. (ES) | 2025-05-28 | — | — | EP | claimed |
| US-20240254485-A1 | SIRNAS TARGETING SLC10A1 TRANSCRIPTS, COMPOSITIONS AND USES THEREOF | Hemoshear Therapeutics, Inc. | 2024-08-01 | — | — | US | claimed |
| US-10752896-B2 | siRNA and their use in methods and compositions for inhibiting the expression of the NRARP gene | SYLENTIS SAU (ES) | 2020-08-25 | — | — | US | claimed |
| US-20180340177-A1 | SIRNA AND THEIR USE IN METHODS AND COMPOSITIONS FOR INHIBITING THE EXPRESSION OF THE NRARP GENE | SYLENTIS SAU (ES) | 2018-11-29 | — | — | US | claimed |
| US-20170251660-A1 | NUCLEOSIDE-CONTAINING COMPOSITIONS AND METHODS FOR TREATING RED BLOOD CELLS | VIACELL, LLC | 2017-09-07 | — | — | US | claimed |
| US-20110229871-A1 | NUCLEOSIDE-CONTAINING COMPOSITIONS AND METHODS FOR TREATING RED BLOOD CELLS | VIACELL, LLC | 2011-09-22 | — | — | US | claimed |
| WO-2011103177-A1 | NUCLEOSIDE-CONTAINING COMPOSITIONS AND METHODS FOR TREATING RED BLOOD CELLS | VIACELL, LLC (US) | 2011-08-25 | — | — | WO | claimed |
| US-20050119214-A1 | Nuclease resistant double-stranded ribonucleic acid | ALNYLAM PHARMACEUTICALS, INC. | 2005-06-02 | — | — | US | claimed |
| WO-2026098677-A1 | DOUBLE-STRANDED RNA FOR REGULATING ALK7 EXPRESSION, CONJUGATE THEREOF, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 苏州时安生物技术有限公司 | 2026-05-15 | — | — | WO | disclosed |
| US-12618068-B2 | Replicase cycling reaction (RCR) and the related SamRNA designs thereof | LIN SHI LUNG (US) | 2026-05-05 | — | — | US | disclosed |
| US-20250354144-A1 | TARGETING MUC1-C WITH A NOVEL ANTISENSE OLIGONUCLEOTIDE FOR THE TREATMENT OF CANCER | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-11-20 | — | — | US | disclosed |
| EP-0549686-A4 | MODIFIED INTERNUCLEOSIDE LINKAGES | GILEAD SCIENCES INC (US) | 1995-01-18 | — | — | EP | disclosed |
| EP-0582157-A1 | Method of purifying nucleoside derivatives | Ajinomoto Co., Inc. (JP) | 1994-02-09 | — | — | EP | disclosed |
| EP-0549686-A1 | MODIFIED INTERNUCLEOSIDE LINKAGES | GILEAD SCIENCES, INC. (US) | 1993-07-07 | — | — | EP | disclosed |
| WO-1992005186-A1 | MODIFIED INTERNUCLEOSIDE LINKAGES | GILEAD SCIENCES (US) | 1992-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119214-A1 | Nuclease resistant double-stranded ribonucleic acid | RNASE1, RNASEH1, RNASEL | SLC28A1 1775/4885SLC28A2 1601/4885SLC29A1 1237/4885 |
| US-12618068-B2 | Replicase cycling reaction (RCR) and the related SamRNA designs thereof | RNGTT, SLIRP, RNMT | SLC28A1 2695/4885SLC28A2 2582/4885SLC29A1 3026/4885 |
| US-20240254485-A1 | SIRNAS TARGETING SLC10A1 TRANSCRIPTS, COMPOSITIONS AND USES THEREOF | SLC20A1, SLC10A1, SLC10A6 | SLC28A1 10/4885SLC28A2 34/4885SLC29A1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.